Advice

in the absence of a submission from the holder of the marketing authorisation:

encorafenib (Braftovi®) is not recommended for use within NHSScotland.

Indication under review: in combination with binimetinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.

Download detailed advice285KB (PDF)

Download

Medicine details

Medicine name:
encorafenib (Braftovi®)
SMC ID:
SMC2865
Indication:

In combination with binimetinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.

Pharmaceutical company
Pierre Fabre Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published
08 September 2025